In vivo experimental models of schizophrenia: mechanisms, features, advantages, disadvantages
Abstract
Keywords
References
- 1. Andreasen NC. Symptoms, signs, and diagnosis of schizophrenia. Lancet 1995;346:477–81.
- 2. Belforte JE, Zsiros V, Sklar ER, Jiang Z, Yu G, Li Y, Quinlan ME, Nakazawa K. Postnatal NMDA reseptor ablation in corticolimbik interneurons confers schizophrenia like phenotypes. Nat Neurosci 2010;13:76–83.
- 3. Andreassen OA, Thompson WK, Dale AM. Boosting the power of schizophrenia genetics by leveraging new statistical tools. Schizophr Bull 2014;40:13–17.
- 4. Uzun Ö. Pozitif – negatif belirtiler. In: Ceylan E, Çetin M, editors. Şizofreni. Vol. 1. İstanbul: Yerküre Tanıtım ve Yayıncılık; 2005. p. 643–56.
- 5. Foussias G, Remington G. Negative symptoms in schizophrenia: avolition and Occam’s razor. Schizophr Bull 2010;36:359–69.
- 6. Bayer TA, Falkai P, Maier W. Genetic and non-genetic vulnerability factors in schizophrenia: the basis of the “two hit hypothesis”. J Psychiatr Res 1999;33:543–8.
- 7. Kim DH, Stahl SM. Antipsychotic drug development. Curr Top Behav Neurosci 2010;4:123–39.
- 8. Taly A. Novel approaches to drug design for the treatment of schizophrenia. Exp Opin Drug Discov 2013;8:1285–96.
Details
Primary Language
English
Subjects
Health Care Administration
Journal Section
Review
Authors
Zeynep Mine Altunay
This is me
0000-0002-7663-7417
United States
Aysel Alphan
This is me
0000-0001-9624-2036
Türkiye
Esat Adıgüzel
*
This is me
0000-0002-1110-5786
Türkiye
Early Pub Date
May 9, 2023
Publication Date
August 30, 2022
Submission Date
May 25, 2022
Acceptance Date
-
Published in Issue
Year 2022 Volume: 16 Number: 2